Breast Flashcards
Selective oEstrogen Receptor Modulators (SERM)
Tamoxifen
It is used in the management of oestrogen receptor-positive breast cancer in PRE-MENOPAUSAL women
Adverse effects
-menstrual disturbance: vaginal bleeding, amenorrhoea
-hot flushes - 3% of patients stop taking tamoxifen due to climacteric side-effects
-venous thromboembolism
-endometrial cancer
Aromatase inhibitors
Anastrozole and letrozole are aromatase inhibitors that reduces peripheral oestrogen synthesis. This is important as aromatisation accounts for the majority of oestrogen production in POSTMENOPAUSAL women and therefore anastrozole is used for ER +ve breast cancer in this group.
Adverse effects
-osteoporosis (NICE recommends a DEXA scan when initiating a patient on aromatase inhibitors)
-hot flushes
-arthralgia, myalgia
-insomnia
Fibroadenoma
Develop from a whole lobule
On examination;
Painless
Smooth
Round
Well circumscribed (well-defined borders)
Firm
Mobile (moves freely under the skin and above the chest wall)
Usually up to 3cm diameter
12% of all breast masses
Over a 2 year period up to 30% will get smaller
No increase in risk of malignancy
If >3cm surgical excision is usual, Phyllodes tumours should be widely excised
NB- fibroadenoma is a solid structure, not cystic (ie. not fluid-filled on USS, and will not fluctuate like a cyst will)
Breast Cyst
The most common breast lump
They can be painful and may fluctuate in size over the menstrual cycle.
On examination, breast cysts are:
Smooth
Well-circumscribed
Mobile
Possibly fluctuant
Small increased risk of breast cancer (especially if younger)
Cysts should be aspirated, those which are blood stained or persistently refill should be biopsied or excised
Breast Cyst
7% of all Western females will present with a breast cyst
Usually presents as a smooth discrete lump (may be fluctuant)
Small increased risk of breast cancer (especially if younger)
Cysts should be aspirated, those which are blood stained or persistently refill should be biopsied or excised
Indications for a mastectomy
Multifocal tumour
Central tumour
Large lesion in small breast
DCIS >4cm
Patient choice
Genetics
Indications for a wide local incision
Solitary lesion
Peripheral tumour
Small lesion in large breast
DCIS <4cm
Patient choice
Risk Factors for breast cancer
BRCA1, BRCA2 genes (40% lifetime risk of breast/ovarian cancer)
1st degree relative premenopausal relative with breast cancer (e.g. mother)
nulliparity, 1st pregnancy > 30 yrs
early menarche, late menopause
combined hormone replacement therapy contraceptive use
past breast cancer
not breastfeeding
ionising radiation
p53 gene mutations
obesity
previous surgery for benign disease
Breast cancer screening
The NHS Breast Screening Programme is offered to women between the ages of 50-70 years. Women are offered a mammogram every 3 years. After the age of 70 years women may still have mammograms but are ‘encouraged to make their own appointments’.
NB- trans women if they have had feminising hormones for 2 years
Subtypes of breast cancer
Invasive ductal carcinoma
Invasive lobular carcinoma
Ductal carcinoma in situ
Lobular carcinoma in situ
Paget’s disease of the nipple
Inflammatory breast cancer
Invasive ductal carcinoma
The most common type
Invasive lobular carcinoma
The 2nd most common type
May not show up on mammography
Ductal carcinoma in situ
Confined to one area
Microcalcifications
Potential to become invasive
Good prognosis
Women with DCIS are usually followed up with an annual clinic appointment and an annual mammogram for five years
Lobular carcinoma in situ
Asymptomatic and undetectable on mammogram
Usually diagnosed incidentally on breast biopsy
Increased risk of invasive carcinoma
Surgical excision of axillary lymph nodes
USS of axilla prior to surgery- biopsy of any abnormal nodes (can then be cleared during surgery)
If no abnormal nodes detected on USS, a sentinel node biopsy can be performed (deduce whether the sentinel node has cancer cells)
NB- axillary clearance may lead to arm lymphedema and functional arm impairment
Radiotherapy
Whole breast radiotherapy is recommended after a woman has had a wide-local excision as this may reduce the risk of recurrence by around two-thirds. For women who’ve had a mastectomy radiotherapy is offered for T3-T4 tumours and for those with four or more positive axillary nodes
NB- If a woman has been previously treated with radiotherapy, she cannot normally be given radiotherapy again, so if she presents with recurrence then mastectomy is usually offered
Chemotherapy
Cytotoxic therapy may be used either prior to surgery (‘neoadjuvanant’ chemotherapy) to downstage a primary lesion or after surgery depending on the stage of the tumour, for example, if there is axillary node disease - FEC-D is used in this situation.
Hormonal therapy
Tamoxifen is still used in pre- and peri-menopausal women.
In post-menopausal women, aromatase inhibitors such as anastrozole and letrozole are used
Biological therapy
Trastuzumab (Herceptin) for tumours that are HER2 positive.
NB- Trastuzumab cannot be used in patients with a history of heart disorders (may want to do echo first)